The biopharma industry experienced a lack of mergers & acquisitions (M&A) activity in 2024, with total values dropping by 51% despite a 17% increase in transactions. However, 2025 is expected to witness a surge in M&A dealmaking, due to factors such as patent expirations, changing political landscape, and companies’ need to diversify their portfolios and access new technologies. Experts believe large biopharma firms have reserved $1.3 trillion for such deals.
DataBreaches.Net: The UK Contemplates Banning Ransom Payments – A Challenging Subject.
Cor blimey! How many times have our mates over at the FBI and CISA urged companies not to pay the ransom in cyber-attacks? It only
